Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 119

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 119
---
4  
    2023 
  
    CASH FLOWS FROM OPERATING ACTIVITIES: 

    Net loss 
    $(42,082) 
    $(30,008)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Stock-based compensation 
     7,605  
     7,368 
  
    Accretion of debt discount 
     79  
     224 
  
    Changes in operating assets and liabilities: 

    Research and development tax credit receivable 
     724  
     6,194 
  
    Other tax receivable 
     309  
     (175)
  
    Prepaid expenses and other current assets 
     1,179  
     2,517 
  
    Prepaid expenses – related party 
     142  
     (108)
  
    Other assets 
     52  
     (32)
  
    Accounts payable and accrued liabilities 
     (1,362) 
     2,695 
  
    Accounts payable and accrued liabilities – related parties 
     (10) 
     26 
  
    Deferred liabilities 
     28  
     (127)
  
    Accrued liability – long-term 
     -  
     (550)
  
    Operating lease liability 
     (25) 
     (4)
  
    Net cash used in operating activities 
     (33,361) 
     (11,980)

    CASH FLOWS FROM FINANCING ACTIVITIES: 

    Net proceeds from sale of common stock and warrants 
     27,789  
     775 
  
    Repayment of debt 
     (10,000) 
     (5,000)
  
    Net proceeds from the exercise of stock options 
     422  
     - 
  
    Net cash provided by (used in) financing activities 
     18,211  
     (4,225)

    Impact on cash from foreign currency translation 
     224  
     (100)

    NET DECREASE IN CASH 
     (14,926) 
     (16,305)
  
    CASH AT BEGINNING OF YEAR 
     35,848  
     52,153 
  
    CASH AT END OF YEAR 
    $20,922  
    $35,848